Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors

Angew Chem Int Ed Engl. 2022 Dec 23;61(52):e202212946. doi: 10.1002/anie.202212946. Epub 2022 Nov 28.

Abstract

During our search for novel myxobacterial natural products, we discovered the thiamyxins: thiazole- and thiazoline-rich non-ribosomal peptide-polyketide hybrids with potent antiviral activity. We isolated four congeners of this unprecedented natural product family with the non-cyclized thiamyxin D fused to a glycerol unit at the C-terminus. Alongside their structure elucidation, we present a concise biosynthesis model based on biosynthetic gene cluster analysis and isotopically labelled precursor feeding. We report incorporation of a 2-(hydroxymethyl)-4-methylpent-3-enoic acid moiety by a GCN5-related N-acetyltransferase-like decarboxylase domain featuring polyketide synthase. The thiamyxins show potent inhibition of RNA viruses in cell culture models of corona, zika and dengue virus infection. Their potency up to a half maximal inhibitory concentration of 560 nM combined with milder cytotoxic effects on human cell lines indicate the potential for further development of the thiamyxins.

Keywords: Antiviral Agents; Biosynthesis; Depsipeptides; Natural Products; Structure Elucidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Multigene Family
  • Myxococcales* / metabolism
  • Polyketide Synthases / genetics
  • Polyketide Synthases / metabolism
  • Polyketides*
  • RNA
  • Zika Virus Infection* / genetics
  • Zika Virus*

Substances

  • RNA
  • Polyketide Synthases
  • Polyketides